The Tuberous Sclerosis Complex (TSC) Fellowship at UAB provides an opportunity for pediatric and adult neurologists with an interest in TSC clinical research and patient care to develop specialized ...

The Company plans to discontinue further clinical development of ganaxolone in TSC. Marinus Pharmaceuticals announced that its phase 3 trial of ganaxolone did not meet the primary end point for the ...

Cassava Sciences' pivot to TSC via a Yale license deal for simufilam addresses both new indications and reputation issues but faces significant clinical and market challenges. Preclinical studies show ...

AUSTIN, Texas, June 30, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (SAVA) (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, ...

Montara’s BrainOnly platform is designed to prevent peripheral side effects and concentrate neurological drugs’ activity in the brain via two-drug combination therapies, comprising its ...

Financing accelerates development of lead candidate AV078, a CNS-penetrant selective mTORC1 inhibitor, and will fund completion of its Phase 2 clinical trial- Round co-led by Luma Group and CTI Life ...

Cytotoxic T lymphocytes play a crucial role in adaptive immunity, primarily defending against tumors and viruses. These cells develop within the thymus gland and undergo rapid activation upon ...

In new study results, researchers from the University of Alabama at Birmingham found that administering the preventive epilepsy treatment vigabatrin prior to seizure onset did not improve ...